keyboard_arrow_up

Acquired Orphan Blood Diseases Therapeutics Market - Global Industry Analysis 2015 Size and Forecast 2019

Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. The acquired orphan blood diseases are developed in the blood after the post fetal life; they are not caused because of genetic reasons. The major orphan blood diseases that contribute to acquired orphan blood diseases are the following: ITP, MDS, MF PNH, and PV.
Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29 percent over the period 2014-2019.

 
Covered in this Report
 
This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.
 
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Acquired Orphan Blood Diseases Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
 
 
Key Regions
 
Americas
APAC
EMEA
 
Key Vendors
 
Alexion Pharmaceuticals
Amgen
Celgene
F. Hoffmann- La Roche
GlaxoSmithKline
Incyte
 
Other Prominent Vendors
 
Cyclacel Pharmaceuticals
CTI Biopharma (Cell Therapeutics)
Eli Lilly
Gilead Sciences
Onconova Therapeutics
MebVax Therapeutics
Novartis
Sanofi
Shire Pharmaceuticals
S* Bio Pte
 
Market Driver
 
Exemption from Pricing Obstacle
For a full, detailed list, view our report
 
Market Challenge
 
Companies Hesitant to Invest in Rare Diseases Therapeutics
For a full, detailed list, view our report
 
Market Trend
 
Benefit from Untapped Market
For a full, detailed list, view our report